Plasma dopamine beta hydroxylase (D.B.H.) activity in Parkinsonian patients under L-dopa, and 2-bromo-alpha-ergocriptine loading. 1979

J Vardi, and S Flechter, and Z Oberman, and M Allelov, and J M Rabey, and M Hertzberg, and M Streifler

Dopamine-Beta-Hydroxylase (D.B.H.)-activity was measured in the plasma of untreated Parkinsonian patients, after tretment with L-dopa and 2-Bromo-alpha-ergocriptine. The findings were compared to the D.B.H.-activity of a matched healthy control group. After L-dopa loading D.B.H.-activity decreased in the Parkinsonian patients by 27.6 +/- 3.1% compared to 16.2 +/- 3.3% (p less than 0.02) in the control group. After 2-Bromo-alpha-ergocriptine laoding the decrease in D.B.H.-activity was 32.6 +/- 4.4% in the parkinsonian patients, and 158 +/- 4.9% (p less than 0.02) in the control group. This reduced D.H.B.-activity after L-dopa loading may reflect an impairment, in the Parkinsonian patients' ability to metaoblize L-dopa. The reduced D.B.H.-activity after treatment with 2-Bromo-alpha-ergocriptine may be explained by a pronounced antagonistic influence of 2-Bromo-alpha-ergocriptine on the presynaptic dopamine receptors, suggesting that presynaptic dopaminergic receptors are involved in Parkinson's disease.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D004299 Dopamine beta-Hydroxylase Dopamine beta-Monooxygenase,Dopamine beta Hydroxylase,Dopamine beta Monooxygenase,beta-Hydroxylase, Dopamine,beta-Monooxygenase, Dopamine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J Vardi, and S Flechter, and Z Oberman, and M Allelov, and J M Rabey, and M Hertzberg, and M Streifler
January 2014, Frontiers in aging neuroscience,
J Vardi, and S Flechter, and Z Oberman, and M Allelov, and J M Rabey, and M Hertzberg, and M Streifler
June 1979, Nihon rinsho. Japanese journal of clinical medicine,
J Vardi, and S Flechter, and Z Oberman, and M Allelov, and J M Rabey, and M Hertzberg, and M Streifler
April 1997, Nihon rinsho. Japanese journal of clinical medicine,
J Vardi, and S Flechter, and Z Oberman, and M Allelov, and J M Rabey, and M Hertzberg, and M Streifler
January 1984, Psychopharmacology,
J Vardi, and S Flechter, and Z Oberman, and M Allelov, and J M Rabey, and M Hertzberg, and M Streifler
January 1980, Nephron,
J Vardi, and S Flechter, and Z Oberman, and M Allelov, and J M Rabey, and M Hertzberg, and M Streifler
March 1976, Clinical endocrinology,
J Vardi, and S Flechter, and Z Oberman, and M Allelov, and J M Rabey, and M Hertzberg, and M Streifler
January 1971, Psychopharmacologia,
J Vardi, and S Flechter, and Z Oberman, and M Allelov, and J M Rabey, and M Hertzberg, and M Streifler
January 1977, The Journal of clinical endocrinology and metabolism,
J Vardi, and S Flechter, and Z Oberman, and M Allelov, and J M Rabey, and M Hertzberg, and M Streifler
July 1974, Research communications in chemical pathology and pharmacology,
J Vardi, and S Flechter, and Z Oberman, and M Allelov, and J M Rabey, and M Hertzberg, and M Streifler
December 1982, Biological psychiatry,
Copied contents to your clipboard!